Earnings summaries and quarterly performance for Terns Pharmaceuticals.
Executive leadership at Terns Pharmaceuticals.
Board of directors at Terns Pharmaceuticals.
Research analysts covering Terns Pharmaceuticals.
Recent press releases and 8-K filings for TERN.
Terns Pharmaceuticals secures exclusive worldwide license for TERN-701
TERN
New Projects/Investments
Product Launch
- On January 16, 2026, Terns Pharmaceuticals, Inc. entered into an Amendment with Hansoh (Shanghai) Healthtech Co., Ltd., granting Terns an exclusive, worldwide license (excluding the Hansoh Territory) for therapeutic products containing TERN-701.
- This license covers patents invented by Hansoh related to TERN-701, replacing a prior non-exclusive license.
- Terns Pharmaceuticals is obligated to pay Hansoh a one-time upfront license fee of $1.0 million and tiered royalties ranging from 0.75% to 1.25% on annual net sales of TERN-701 products in its licensed territory.
Jan 22, 2026, 9:07 PM
Terns Pharmaceuticals Highlights TERN-701 Clinical Data and 2026 Milestones
TERN
Product Launch
New Projects/Investments
- Terns Pharmaceuticals' TERN-701, an allosteric BCR-ABL inhibitor for CML, demonstrated 75% Major Molecular Response (MMR) achievement by 24 weeks at doses ≥320 mg in the CARDINAL study, alongside an encouraging safety and tolerability profile.
- The company has several significant milestones planned for TERN-701 in 2026, including pivotal dose selection, EOP2 regulatory interaction (mid-26), an updated and expanded CARDINAL data release (2H26), and the initiation of a 2L+ pivotal trial (late '26/early '27).
- Terns Pharmaceuticals reported a strong financial position with approximately $1.0 billion in cash at year-end 2025, which is expected to provide a cash runway into 2031, covering the potential first approval and commercial launch of TERN-701.
Jan 12, 2026, 11:45 PM
Terns Pharmaceuticals Highlights Positive TERN-701 Clinical Data and Outlines 2026 Milestones
TERN
Guidance Update
New Projects/Investments
Product Launch
- Terns Pharmaceuticals reported a strong 2025 and anticipates an exciting 2026, supported by $1 billion in cash on its balance sheet, which removes financing overhang until commercial launch.
- The company's drug candidate, TERN-701, is positioned as a potential best-in-disease therapy for Chronic Myeloid Leukemia (CML), demonstrating 75% Major Molecular Response (MMR) achievement at 24 weeks in a highly refractory patient population at doses of 320 milligrams and above. This rate is trending three times greater than asciminib's MMR achievement rates.
- TERN-701 exhibits a favorable safety and tolerability profile with no dose-limiting toxicities, pancreatic toxicity, or significant blood pressure changes, and offers convenience with once-daily dosing without regard to food.
- Key upcoming milestones for 2026 include dose selection for TERN-701, regulatory interactions with the FDA, and the initiation of 2L+ and first-line trials, with additional data expected to be shared.
Jan 12, 2026, 11:45 PM
Terns Provides Update on Terns 701 Development and Financial Position
TERN
Guidance Update
New Projects/Investments
Product Launch
- Terns reported a cash balance of $1 billion on its balance sheet, which is expected to remove any financing overhang for the company until the commercial launch of Terns 701.
- Terns 701 demonstrated a 75% Major Molecular Response (MMR) achievement rate at 24 weeks in a highly refractory patient population at doses of 320 milligrams and above, with a favorable safety and tolerability profile, including no dose-limiting toxicities.
- The company plans to select a dose for pivotal trials in the first half of 2026, followed by regulatory interactions with the FDA to discuss trial design and initiate second-line plus and first-line trials for Terns 701.
- Terns believes Terns 701 has the potential to be a best-in-disease therapy for CML, citing its efficacy, safety, and once-daily dosing without regard to food, and anticipates gaining a majority market share in the frontline setting.
Jan 12, 2026, 11:45 PM
Terns Pharmaceuticals Highlights Terns 701 as Potential Best-in-Disease CML Therapy and Strong Financial Position
TERN
Product Launch
Guidance Update
New Projects/Investments
- Terns Pharmaceuticals presented Terns 701 as a potential best-in-disease therapy for Chronic Myeloid Leukemia (CML), showcasing 75% Major Molecular Response (MMR) achievement at 24 weeks in a highly refractory patient population at doses of 320 mg and above, along with a favorable safety profile.
- The company plans to select a dose for pivotal trials and engage with the FDA in the first half of 2026, aiming to initiate second-line plus and first-line trials for Terns 701.
- Terns reported a strong financial position with $1 billion in cash on its balance sheet, which is expected to fund the company through the commercial launch of Terns 701.
Jan 12, 2026, 11:45 PM
TERN-701 Demonstrates Strong Efficacy for CML and Outlines 2026 Milestones
TERN
Product Launch
New Projects/Investments
Guidance Update
- TERN-701 is positioned as a potential best-in-disease therapy for the $5B+ CML market, showing unprecedented efficacy with 75% MMR achievement by 24 weeks at doses ≥320 mg QD, alongside an encouraging safety and tolerability profile.
- The company maintains a strong financial position with approximately $1.0B in cash, providing a runway into 2031 which includes the potential first approval and commercial launch of TERN-701.
- Key milestones planned for 2026 include pivotal dose selection and EOP2 regulatory interaction (mid-26), an update and expansion of CARDINAL data (2H26), and the initiation of a 2L+ pivotal trial (late '26/early '27).
- TERN-701's 75% MMR achievement rate at doses ≥320 mg in the CARDINAL study significantly exceeds Asciminib's 24-25.5% MMR achievement rate observed in its Phase 1 and Phase 3 studies by 24 weeks.
Jan 12, 2026, 12:00 PM
Terns Pharmaceuticals Highlights 2026 Priorities and Strong Financial Position
TERN
Guidance Update
New Projects/Investments
Product Launch
- Terns Pharmaceuticals reported unaudited cash, cash equivalents, and marketable securities of approximately $1.0 billion as of December 31, 2025, which is projected to provide a cash runway into 2031.
- The company's lead program, TERN-701 for CML, received U.S. FDA Fast Track designation in Q4 2025 and demonstrated unprecedented efficacy with a 75% Major Molecular Response (MMR) rate by 24 weeks in evaluable patients from the CARDINAL Phase 1/2 trial.
- Key milestones for TERN-701 in 2026 include pivotal dose selection, End of Phase 2 regulatory interaction with the U.S. FDA, and the initiation of the first pivotal trial in late 2026 / early 2027.
Jan 9, 2026, 9:05 PM
Terns Pharmaceuticals Announces Pricing of Upsized Public Offering
TERN
New Projects/Investments
- Terns Pharmaceuticals announced the pricing of an upsized underwritten public offering of 16,250,000 shares of its common stock at $40.00 per share.
- The offering is expected to generate $650 million in gross proceeds and is anticipated to close on December 11, 2025. Underwriters have a 30-day option to purchase up to an additional 2,437,500 shares.
- The net proceeds from the offering will be used to fund research, clinical trials, development, and manufacturing of key product candidates, including TERN-701, initial activities for its potential future commercial launch, and for working capital and general corporate purposes.
Dec 10, 2025, 4:30 AM
Terns Pharmaceuticals Announces Proposed Public Offering
TERN
New Projects/Investments
- Terns Pharmaceuticals, Inc. has commenced a proposed underwritten public offering of $400 million of shares of its common stock and/or pre-funded warrants.
- The company also expects to grant the underwriters a 30-day option to purchase up to an additional $60 million of common stock.
- Terns intends to use the net proceeds to fund research, clinical trials, development, and manufacturing of key product candidates, including TERN-701, as well as for initial activities in preparation for its potential future commercial launch and for general corporate purposes.
- TERN-701 is described as a highly selective, allosteric BCR-ABL inhibitor with a potentially best-in-disease profile for CML.
Dec 9, 2025, 11:12 AM
Terns Pharmaceuticals Presents Positive Tern 701 Clinical Data for CML
TERN
New Projects/Investments
- Terns Pharmaceuticals presented unprecedented efficacy and safety data for Tern 701, an investigational oral allosteric BCR-ABL inhibitor for chronic myeloid leukemia (CML).
- In the Cardinal phase 1 study, Tern 701 demonstrated 75% Major Molecular Response (MMR) and 36% Deep Molecular Response (DMR) by 24 weeks at the recommended phase two dose range of 320 milligrams and above.
- The drug exhibited a favorable safety profile, with most treatment-emergent adverse events being low-grade, all grade 3 adverse events less than 10%, and no pancreatic toxicity or clinically significant changes in blood pressure.
- Terns plans to share expanded, longer-term data from the Cardinal study in 2026, select a single dose for pivotal trials, and gain regulatory alignment for future studies.
Dec 8, 2025, 9:30 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more